Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immatics (IMTX)
NASDAQ:IMTX
Holding IMTX?
Track your performance easily
IMTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.15 - $13.77
Previous Close$11.73
Volume537.42K
Average Volume (3M)331.93K
Market Cap
$1.18B
Enterprise Value$724.24M
Total Cash (Recent Filing)€425.89M
Total Debt (Recent Filing)€15.40M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Nov 12, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding103,110,000
10 Day Avg. Volume362,735
30 Day Avg. Volume331,926
Standard Deviation0.14
R-Squared0.11
Alpha-0.00218
Financial Highlights & Ratios
Price to Book (P/B)3.91
Price to Sales (P/S)16.17
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$17.33Price Target Upside47.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Immatics News
PremiumCompany Announcements
Immatics N.V. Unveils Mid-Year Financial Outlook
PremiumCompany Announcements
Immatics N.V. Appoints New Board Member
PremiumCompany Announcements
Immatics N.V. AGM Concludes SuccessfullyBulls Say, Bears Say
Bulls Say
Clinical DataThe treatment of 30 patients with GEN1 led to a 55% confirmed overall response rate with a median duration of response of 13.5 months.
Pipeline ProgressThe updated IMA203 data showed a confirmed overall response rate increase to 55% from 50%, supporting plans to begin a registration-directed Phase II/III study in melanoma.
Safety ProfileTreatment with GEN1 has maintained a favorable safety profile with mostly mild to moderate side effects and no Grade 5 adverse events.
Bears Say
Clinical TrialsTwo Grade 5 events were disclosed, one each for IMA401 and IMA203CD8.
PartnershipsIts partnership with Genmab was terminated.
Stock PerformanceIMTX shares have underperformed since the last update.
---
Ownership Overview
0.00%
Insiders
13.60% Mutual Funds
55.66% Other Institutional Investors
30.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMTX FAQ
What was Immatics’s price range in the past 12 months?
Immatics lowest stock price was $7.15 and its highest was $13.77 in the past 12 months.
What is Immatics’s market cap?
Currently, no data Available
When is Immatics’s upcoming earnings report date?
Immatics’s upcoming earnings report date is Nov 12, 2024 which is in 65 days.
How were Immatics’s earnings last quarter?
Immatics released its earnings results on Aug 13, 2024. The company reported -$0.188 earnings per share for the quarter, beating the consensus estimate of -$0.312 by $0.124.
Is Immatics overvalued?
According to Wall Street analysts Immatics’s price is currently Undervalued.
Does Immatics pay dividends?
Immatics does not currently pay dividends.
What is Immatics’s EPS estimate?
Immatics’s EPS estimate is -$0.32.
How many shares outstanding does Immatics have?
Immatics has 103,053,444 shares outstanding.
What happened to Immatics’s price movement after its last earnings report?
Immatics reported an EPS of -$0.188 in its last earnings report, beating expectations of -$0.312. Following the earnings report the stock price went up 1.231%.
Which hedge fund is a major shareholder of Immatics?
Among the largest hedge funds holding Immatics’s share is Perceptive Advisors LLC. It holds Immatics’s shares valued at 94M.
---
Immatics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.33 (47.74% Upside)
$17.33 (47.74% Upside)
Blogger Sentiment
Bullish
IMTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.78%
12-Months-Change
Fundamentals
Return on Equity
-24.37%
Trailing 12-Months
Asset Growth
50.15%
Trailing 12-Months
Company Description
Immatics
Immatics NV is engaged in discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly hard-to-treat solid cancers.
---
IMTX Stock 12 Month Forecast
Average Price Target
$17.33
▲(47.74% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Fate Therapeutics
―
Crispr Therapeutics AG
―
Editas Medicine
―
Best Analysts Covering IMTX
1 Year
1 Year Success Rate
9/21 ratings generated profit
1 Year Average Return
-0.55%
reiterated a buy rating 26 days ago
Copying Jonathan Chang's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -0.55% per trade.
---